Skip to main content
Contact Us
Subscribe
E-Edition
46°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
17.33
-0.49 (-2.75%)
Official Closing Price
Updated: 7:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
December 05, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
December 04, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Is SoundHound AI a Millionaire-Maker Stock?
December 03, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Generic Drug Stocks Ready to Surge in 2025
November 27, 2024
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.
Via
MarketBeat
Topics
Government
Intellectual Property
Exposures
Intellectual Property
Political
Product Safety
Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report
November 06, 2024
The company also raised its outlook for the year.
Via
Investor's Business Daily
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
November 25, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
November 15, 2024
Via
Benzinga
Teva to Present at the Jefferies London Healthcare Conference
November 08, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
November 06, 2024
TEVA earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today
October 29, 2024
Via
Benzinga
A Closer Look at 4 Analyst Recommendations For Teva Pharmaceutical Indus
October 23, 2024
Via
Benzinga
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
November 06, 2024
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion.
Via
Benzinga
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
November 06, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
November 01, 2024
Amid the election, and a Fed rate vote, earnings season roars ahead.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
November 01, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
November 01, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Statement on European Commission Decision; Company to Appeal
October 31, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
October 22, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
October 17, 2024
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes
October 11, 2024
Teva Pharmaceuticals will pay $450 million to resolve allegations of kickback schemes involving Medicare copays and price-fixing. This settlement is part of a broader crackdown on healthcare fraud...
Via
Benzinga
Topics
Fraud
Exposures
Legal
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
October 10, 2024
Via
Benzinga
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
October 08, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
October 03, 2024
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.
Via
Benzinga
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
October 03, 2024
From
Teva Pharmaceutical Industries Ltd; mAbxience
Via
GlobeNewswire
Teva Launches Generic Version Of Sandostatin In The US
October 01, 2024
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down Tuesday. Here's what you need to know.
Via
Benzinga
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
October 01, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
September 30, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
September 30, 2024
Via
Benzinga
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
September 30, 2024
Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the...
Via
Benzinga
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.